FY2025 EPS Estimates for Perrigo Raised by Zacks Research

Perrigo Company plc (NYSE:PRGO) – Stock analysts at Zacks Research boosted their FY2025 earnings estimates for Perrigo in a research report issued to clients and investors on Monday, February 16th. Zacks Research analyst Team now forecasts that the company will post earnings of $2.77 per share for the year, up from their previous estimate of $2.76. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Perrigo’s current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Perrigo’s Q4 2025 earnings at $0.80 EPS, FY2026 earnings at $3.00 EPS, Q3 2027 earnings at $0.81 EPS, Q4 2027 earnings at $0.84 EPS and FY2027 earnings at $3.18 EPS.

Other equities research analysts have also recently issued reports about the company. Weiss Ratings reissued a “sell (d+)” rating on shares of Perrigo in a report on Monday, December 22nd. Argus raised Perrigo to a “hold” rating in a research report on Wednesday, January 14th. JPMorgan Chase & Co. cut their price target on shares of Perrigo from $20.00 to $18.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. Canaccord Genuity Group dropped their target price on Perrigo from $40.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, November 6th. Finally, Jefferies Financial Group reduced their price target on Perrigo from $27.00 to $23.00 and set a “hold” rating on the stock in a report on Monday, October 27th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $20.33.

Perrigo Trading Up 2.2%

Shares of Perrigo stock opened at $14.90 on Thursday. The company’s fifty day simple moving average is $14.26 and its 200-day simple moving average is $17.90. Perrigo has a 1-year low of $12.17 and a 1-year high of $30.93. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.51 and a quick ratio of 1.44. The stock has a market capitalization of $2.05 billion, a PE ratio of -39.20, a P/E/G ratio of 1.31 and a beta of 0.39.

Institutional Investors Weigh In On Perrigo

Several large investors have recently modified their holdings of the business. Geneos Wealth Management Inc. boosted its stake in shares of Perrigo by 439.1% during the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after purchasing an additional 786 shares in the last quarter. Huntington National Bank boosted its position in Perrigo by 237.8% during the 2nd quarter. Huntington National Bank now owns 1,054 shares of the company’s stock valued at $28,000 after acquiring an additional 742 shares in the last quarter. Hantz Financial Services Inc. increased its holdings in shares of Perrigo by 101.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 1,234 shares of the company’s stock valued at $33,000 after acquiring an additional 620 shares during the period. Kestra Investment Management LLC increased its holdings in shares of Perrigo by 57.1% in the 2nd quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock valued at $47,000 after acquiring an additional 642 shares during the period. Finally, Jones Financial Companies Lllp raised its position in shares of Perrigo by 89.1% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,778 shares of the company’s stock worth $38,000 after acquiring an additional 838 shares in the last quarter. Institutional investors own 95.91% of the company’s stock.

Perrigo Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 24th. Stockholders of record on Monday, March 2nd will be paid a dividend of $0.29 per share. The ex-dividend date is Monday, March 2nd. This represents a $1.16 annualized dividend and a dividend yield of 7.8%. Perrigo’s dividend payout ratio (DPR) is currently -305.26%.

Trending Headlines about Perrigo

Here are the key news stories impacting Perrigo this week:

• Positive Sentiment: Board-approved quarterly dividend of $0.29/share (annualized $1.16) with a ~7.8% yield; payable Mar. 24 to holders of record Mar. 2 — supports income-oriented demand and helps explain buying interest in this beaten-down name. Perrigo Announces Quarterly Dividend Perrigo declares $0.29 dividend
• Positive Sentiment: Analyst estimate revisions: Zacks Research has nudged several near-term and FY estimates slightly higher (FY2026/FY2027 upgrades across notes), signaling modestly improved analyst expectations for earnings recovery. (Source: Zacks/MarketBeat summary)
• Neutral Sentiment: Market commentary lists Perrigo among high-yield, value-oriented healthcare names — that profile can attract income and value buyers but also keeps the stock tied to yield narratives rather than growth catalysts. (MarketBeat feature)
• Neutral Sentiment: Company expected to report quarterly results soon; presence of an upcoming earnings print increases event risk/volatility but also provides a catalyst for re-rating. Perrigo (PRGO) Expected to Announce Quarterly Earnings on Thursday
• Negative Sentiment: Zacks earnings preview warns Q4 results are expected to decline and that the company lacks the setup for a likely beat — a weaker report could reverse recent gains and pressure the stock. Earnings Preview: Perrigo (PRGO) Q4 Earnings Expected to Decline
• Negative Sentiment: Ongoing legal and integration risks (noted in coverage of the firm’s past Nestlé-related acquisition and related class-action exposure) remain a downside overhang that could limit valuation expansion despite the high yield. (Market commentary)

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.